These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16799653)

  • 41. Distal pancreatectomy with splenectomy for the management of splenic hilum metastasis in cytoreductive surgery of epithelial ovarian cancer.
    Xiang L; Tu Y; He T; Shen X; Li Z; Wu X; Yang H
    J Gynecol Oncol; 2016 Nov; 27(6):e62. PubMed ID: 27550408
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperthermic intraperitoneal chemotherapy after extensive cytoreductive surgery in patients with primary advanced epithelial ovarian cancer: interim analysis of a phase II study.
    Lim MC; Kang S; Choi J; Song YJ; Park S; Seo SS; Park SY
    Ann Surg Oncol; 2009 Apr; 16(4):993-1000. PubMed ID: 19169758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer.
    Gillette-Cloven N; Burger RA; Monk BJ; McMeekin DS; Vasilev S; DiSaia PJ; Kohler MF
    J Am Coll Surg; 2001 Dec; 193(6):626-32. PubMed ID: 11768679
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Removal of the entire internal iliac vessel system is a feasible surgical procedure for locally advanced ovarian carcinoma adhered firmly to the pelvic sidewall.
    Nishikimi K; Tate S; Matsuoka A; Shozu M
    Int J Clin Oncol; 2019 Aug; 24(8):941-949. PubMed ID: 30891652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer.
    Graziosi L; Cantarella F; Mingrone E; Gunnellini M; Cavazzoni E; Liberati M; Donini A
    Ann Ital Chir; 2013; 84(5):551-6. PubMed ID: 24140896
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of effectiveness of the PlasmaJet surgical device in the treatment of advanced stage ovarian cancer (PlaComOv-study): study protocol of a randomized controlled trial in the Netherlands.
    Nieuwenhuyzen-de Boer GM; Hofhuis W; Reesink-Peters N; Ewing-Graham PC; Schoots IG; Beltman JJ; Piek JMJ; Baalbergen A; Kooi GS; van Haaften A; van Huisseling H; Haans L; Dorman M; van Beekhuizen HJ
    BMC Cancer; 2019 Jan; 19(1):58. PubMed ID: 30642296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW; Orr P; Kern DH
    Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Cancer; 1995 Nov; 76(9):1606-14. PubMed ID: 8635065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy.
    Muntz HG; Jones MA; Goff BA; Fuller AF; Nikrui N; Rice LW; Tarraza HM
    Cancer; 1995 Oct; 76(7):1209-13. PubMed ID: 8630899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa.
    Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
    Eur J Obstet Gynecol Reprod Biol; 2019 May; 236():214-223. PubMed ID: 30905627
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
    Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
    Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up.
    Scholz HS; Tasdemir H; Hunlich T; Turnwald W; Both A; Egger H
    Gynecol Oncol; 2007 Sep; 106(3):591-5. PubMed ID: 17619055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Chen J; Tang MQ; Liu Q; Cai SM
    J Surg Oncol; 2000 Sep; 75(1):24-30. PubMed ID: 11025458
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Third National Ovarian Consensus. 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"].
    Gallardo-Rincón D; Cantú-de-León D; Alanís-López P; Alvarez-Avitia MA; Bañuelos-Flores J; Herbert-Núñez GS; Oñate-Ocaña LF; Pérez-Montiel MD; Rodríguez-Trejo A; Ruvalcaba-Limón E; Serrano-Olvera A; Ortega-Rojo A; Cortés-Esteban P; Erazo-Valle A; Gerson-Cwilich R; De-la-Garza-Salazar J; Green-Renner D; León-Rodríguez E; Morales-Vásquez F; Poveda-Velasco A; Aguilar-Ponce JL; Alva-López LF; Alvarado-Aguilar S; Alvarado-Cabrero I; Aquino-Mendoza CA; Aranda-Flores CE; Bandera-Delgado A; Barragán-Curiel E; Barrón-Rodríguez P; Brom-Valladares R; Cabrera-Galeana PA; Calderillo-Ruiz G; Camacho-Gutiérrez S; Capdeville-García D; Cárdenas-Sánchez J; Carlón-Zárate E; Carrillo-Garibaldi O; Castorena-Roji G; Cervantes-Sánchez G; Coronel-Martínez JA; Chanona-Vilchis JG; Díaz-Hernández V; Escudero-de-los Ríos P; Garibay-Cerdenares O; Gómez-García E; Herrera-Montalvo LA; Hinojosa-García LM; Isla-Ortiz D; Jiménez-López J; Lavín-Lozano AJ; Limón-Rodriguez JA; López-Basave HN; López-García SC; Maffuz-Aziz A; Martínez-Cedillo J; Martínez-López DM; Medina-Castro JM; Melo-Martínez C; Méndez-Herrera C; Montalvo-Esquivel G; Morales-Palomares MA; Morán-Mendoza A; Morgan-Villela G; Mota-García A; Muñoz-González DE; Ochoa-Carrillo FJ; Pérez-Amador M; Recinos-Money E; Rivera-Rivera S; Robles Flores JU; Rojas-Castillo E; Rojas-Marín C; Salas-Gonzáles E; Sámano-Nateras L; Santibañez-Andrade M; Santillán-Gómez A; Silva-García A; Silva JA; Solorza-Luna G; Tabarez-Ortiz AR; Talamás-Rohana P; Tirado-Gómez LL; Torres-Lobatón A; Quijano-Castro F
    Rev Invest Clin; 2011; 63(6):665-702. PubMed ID: 23650680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
    Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL
    Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer.
    Cascales Campos P; Gil J; Parrilla P
    Eur J Surg Oncol; 2014 Aug; 40(8):970-5. PubMed ID: 24035502
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
    Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma.
    Reichman TW; Cracchiolo B; Sama J; Bryan M; Harrison J; Pliner L; Harrison LE
    J Surg Oncol; 2005 May; 90(2):51-6; discussion 56-8. PubMed ID: 15844187
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.